METHODS FOR TREATING HEPATITIS C

1 .- 75 . (canceled)

76 . A compound of formula I

or a pharmaceutically acceptable salt thereof, wherein:

X is: (a) -nitro;

(b) —COR a , wherein R a is: (1) —C 1 to C 6 alkyl, (2) -cyclopropyl, (3) -cyclobutyl, (4) -cyclopentyl, (5) -cyclohexyl, (6) -aryl optionally substituted with an alkoxy or a halogen, or (7) -amino disubstituted with C 1 to C 6 alkyl or one C 1 to C 6 alkyl substituent and one cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl substituent;

(c) —COOR x , wherein R x is a C 1 to C 6 alkyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl;

(d) -formyl;

(e) -aryl optionally substituted with an alkoxy; or,

(f) -hydrogen;

Y is: -aryl, optionally substituted with one or more of the following:

(1) -alkoxy optionally substituted with: (i) -alkoxy, (ii) -hydroxy, (iii) -one or more halogen(s), (iv) -5 or 6 membered heterocycle, optionally substituted with: —C 1 to C 6 alkyl, -cyclopropyl, -cyclobutyl, -cyclopentyl, -cyclohexyl, or -hydroxy, (v) -amino optionally substituted with one or more C 1 to C 6 alkyl(s), cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, (vi) —NR i SO 2 R x , wherein R x is as defined above and R 1 is: -hydrogen, —C 1 to C 6 alkyl, -cyclopropyl, -cyclobutyl, -cyclopentyl, -cyclohexyl, —COR x , wherein R x is as defined above, -haloalkyl, or -haloalkoxy, (vii) —NR j COR k , wherein R k is: —C 1 to C 6 alkyl, -cyclopropyl, -cyclobutyl, -cyclopentyl, -cyclohexyl, -hydrogen, or -amino optionally substituted with one or more C 1 to C 6 alkyl(s), cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, and R j is: -hydrogen, —C 1 to C 6 alkyl, -cyclopropyl, -cyclobutyl, -cyclopentyl, -cyclohexyl, —COR x , wherein R x is as defined above, -haloalkyl, or -haloalkoxy, (viii) —N═N + ═N − , or (ix) —COR l , wherein R l is a 5 or 6 membered heterocycle optionally substituted with a hydroxy,

(2) -amino optionally substituted with one or more C 1 to C 6 alkyl(s), cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl,

(3) —C 1 to C 6 alkyl, -cyclopropyl, -cyclobutyl, -cyclopentyl, or -cyclohexyl, optionally substituted with: —NHSO 2 R x , wherein R x is as defined above, or —NR x SO 2 R x , wherein R x is as defined above,

(4) -haloalkoxy,

(5) -halogen,

(6) -hydroxy,

(7) —COOR x , wherein R x is as defined above,

(8) —COR m , wherein R m is: (i) -amino optionally substituted with one or more C 1 to C 6 alkyl(s), cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, wherein the one or more C 1 to C 6 alkyl(s), cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl are optionally substituted with: -hydroxy, -5 or 6 membered heterocycle, -amino optionally substituted with one or more C 1 to C 6 alkyl(s), cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or -alkoxy, (ii) -3 to 7 membered heterocycle, optionally substituted with a C 1 to C 6 alkyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, wherein C 1 to C 6 alkyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl is optionally substituted with a disubstituted amino, wherein amino is disubstituted with C 1 to C 6 alkyl or one C 1 to C 6 alkyl substituent and one cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl substituent, or (iii) —NHR n , wherein R n is: —CH 2 CONH 2 , or -aryl optionally substituted with: —C 1 to C 6 alkyl, -cyclopropyl, -cyclobutyl, -cyclopentyl, -cyclohexyl, -one or more halogen(s), -nitro, or -one or more alkoxy(s),

(9) —NR o COR p , wherein R p is: (i) —C 1 to C 6 alkyl, -cyclopropyl, -cyclobutyl, -cyclopentyl or -cyclohexyl, optionally substituted with: -halogen, -alkoxy, or -aryl, (ii) -5 or 6 membered heterocycle, (iii) -aryl, optionally substituted with a halogen, (iv) -5 or 6 membered heteroaryl optionally substituted with one or more C 1 to C 6 alkyl(s), cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, (v) hydrogen, or

and wherein R o is: (i) -hydrogen, (ii) —C 1 to C 6 alkyl, -cyclopropyl, -cyclobutyl, -cyclopentyl or -cyclohexyl, (iii) —COR x , wherein R x is as defined above, (iv) -haloalkyl, or (v) -haloalkoxy,

(10) —NR q CONR q R r , wherein R q is: (i) -hydrogen, (ii) —C 1 to C 6 alkyl, -cyclopropyl, -cyclobutyl, -cyclopentyl or -cyclohexyl, (iii) -haloalkyl, (iv) -haloalkoxy, or (v) —COR x , wherein R x is as defined above, and wherein R r is: (1) -aryl optionally substituted with:

—C 1 to C 6 alkyl, -cyclopropyl, -cyclobutyl, -cyclopentyl, -cyclohexyl, -haloalkyl, —OR s , wherein R s is aryl, or —COOR x , wherein R x is as defined above, (ii) —C 1 to C 6 alkyl, -cyclopropyl, -cyclobutyl, -cyclopentyl, or -cyclohexyl, optionally substituted with one or more of the following: -halogen, -alkenyl, -aryl, or —COOR x , wherein R x is as defined above, (iii) —COOR x , wherein R x is as defined above, (iv) -cyclopropyl, (v) -cyclobutyl, (vi) -cyclopentyl, (vii) -cyclohexyl or (viii) -cyclopropylmethyl,

(11) —NR t COOR u , wherein R u is: (i) —C 1 to C 12 alkyl, -cyclopropyl, -cyclobutyl, -cyclopentyl, or -cyclohexyl, wherein C 1 to C 12 alkyl, -cyclopropyl, -cyclobutyl, -cyclopentyl, or -cyclohexyl are optionally substituted with: (a) -aryl optionally substituted with a C 1 to C 6 alkyl, -cyclopropyl, -cyclobutyl, -cyclopentyl, or -cyclohexyl, or an alkoxy, (b) -alkenyl, (c) -alkoxy, (d) -alkynyl, (e) -halogen, or (f) -5 or 6 membered heterocycle, (ii) aryl, optionally substituted with: -alkoxy, -halogen, —C 1 to C 6 alkyl, -cyclopropyl, -cyclobutyl, -cyclopentyl, or -cyclohexyl, (iii) -5 or 6 membered heterocycle, (iv) -cyclopropyl, (v) -cyclobutyl, (vi) -cyclopentyl, (vii) -cyclohexyl, (viii) -cyclopropylmethyl, or (ix) -cyclopropylethyl, and R t is: (i) -hydrogen, (ii) —C 1 to C 6 alkyl, -cyclopropyl, -cyclobutyl, -cyclopentyl, or -cyclohexyl, —COR x , wherein R x is as defined above, (iv) -haloalkyl, or (v) -haloalkoxy,

(12) —NR v SO 2 R w , wherein R v is: (i) -hydrogen, (ii) —COR x , wherein R x is as defined above, or (iii) —C 1 to C 6 alkyl, -cyclopropyl, -cyclobutyl, -cyclopentyl, or -cyclohexyl, wherein C 1 to C 6 alkyl, -cyclopropyl, -cyclobutyl, -cyclopentyl, or -cyclohexyl is optionally substituted with: -halogen, —COR x , wherein R x is as defined above, —OCOR x , wherein R x is as defined above, -hydroxy, or -alkoxy, and wherein R w is: (i) —C 1 to C 6 alkyl, -cyclopropyl, -cyclobutyl, -cyclopentyl, or -cyclohexyl, wherein C 1 to C 6 alkyl, -cyclopropyl, -cyclobutyl, -cyclopentyl, or -cyclohexyl is optionally substituted with: -halogen, -haloalkyl, -aryl, or -5 or 6 membered heterocycle, (ii) —C 2 to C 6 alkenyl, (iii) -mono-alkyl-amino or -dialkyl-amino optionally substituted on alkyl with a halogen, (iv) amino disubstituted with one C 1 to C 6 alkyl substituent and one cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl substituent, (v) -5 or 6 membered heterocycle, or (vi) -5 or 6 membered heteroaryl optionally substituted with: —C 1 to C 6 alkyl, -cyclopropyl, -cyclobutyl, -cyclopentyl, or -cyclohexyl, -5 or 6 membered heterocycle, of

optionally substituted with a C 1 to C 6 alkyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, wherein R y is a C 1 to C 6 alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or hydrogen,

wherein R z is hydrogen or a C 1 to C 6 alkyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, optionally substituted with aryl,

(20) —SR x , wherein R x is as defined above,

(21) —SO 2 R aa , wherein R aa is: (i) —C 1 to C 6 alkyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, (ii) -amino, (iii) -mono-alkyl-amino or -dialkyl-amino optionally substituted on alkyl with a hydroxy or a —COOR x , wherein R x is as defined above, (iv) amino disubstituted with one C 1 to C 6 alkyl substituent and one cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl substituent; or (v) -5 or 6 membered heteroaryl,

(22) -aryl, or

(23) —NHR bb , wherein R bb is:

(iii) —C(═S)NH 2 , or (iv) —PO(OR x ) 2 , wherein R x is as defined above;

Z is: (a) —COOR x , wherein R x is as defined above;

(b) -cyclopropyl;

(c) -cyclobutyl;

(d) -cyclopentyl;

(e) -cyclohexyl;

(f) -cyclopropylmethyl;

(g) -cyclobutylmethyl; or

(h) -cyclopentylmethyl;

R is: (a) -hydrogen;

(b) -halogen; or

(c) -alkoxy;

R 1 is: (a) -hydrogen;

(b) -hydroxy;

(c) -halogen;

(d) -haloalkyl;

(e) -nitro;

(f) -5 or 6 membered heteroaryl;

(g) -5 or 6 membered heterocycle;

(h) -alkoxy optionally substituted with: (1) -one or more halogen(s), (2) -aryl, or (3) -5 or 6 membered heterocycle;

(i) -aryl optionally substituted with an alkoxy;

(j) —COR x , wherein R x is as defined above;

(k) —C 1 to C 6 alkyl, -cyclopropyl, -cyclobutyl, -cyclopentyl, or -cyclohexyl, optionally substituted with (i) a -dialkyl-amino (ii) amino disubstituted with one C 1 to C 6 alkyl substituent and one cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl substituent; or (iii) a 5 or 6 membered heterocycle; or

R 1 joins together with R 2 to form:

R 2 is: (a) -nitro;

(b) -hydrogen;

(c) -halogen;

(d) -hydroxy;

(e) —C 1 to C 6 alkyl, -cyclopropyl, -cyclobutyl, -cyclopentyl, or -cyclohexyl, optionally substituted with one or more halogen(s);

(f) -amino;

(g) -alkoxy optionally substituted with: (1) -one or more halogen(s), (2) —OCOR x , wherein R x is as defined above, (3) -amino disubstituted with C 1 to C 6 alkyl and optionally substituted on alkyl with an alkoxy, (4) amino disubstituted with one C 1 to C 6 alkyl substituent and one cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl substituent; (5) -5 or 6 membered heterocycle optionally substituted with a C 1 to C 6 alkyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, (6) -5 or 6 membered heteroaryl, or (7) -aryl;

(h) —COOR x , wherein R x is as defined above;

(i) -haloalkyl;

(j) -amide optionally substituted with: (l) -hydroxy, or (2) -aryl;

(k) -5 or 6 membered heteroaryl;

(l) —OCOR x , wherein R x is as defined above;

(m) —NHCOR jj , wherein R jj is: (1) -alkoxy, or (2) -amino optionally substituted with one or more C 1 to C 6 alkyl(s), cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl;

(n) —OR kk , wherein R kk is a 5 to 6 membered heteroaryl;

(o) —NHSO 2 R x , wherein R x is as defined above; or

R 2 joins together with R 1 to form:

R 3 is:

(a) -hydrogen; or

(b) —CH 2 OCOR x , and R x is as defined above;

provided that when X is phenyl substituted with alkoxy, then R is hydrogen, R 1 is a halogen, R 2 is hydrogen, and R 3 is hydrogen.

77 . The compound of claim 76 , wherein:

Y is (a) aryl, optionally substituted with one or more of the following:

(1) -amino optionally substituted with one or more C 1 to C 6 alkyl(s), cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl,

(2) —C 1 to C 6 alkyl, -cyclopropyl, -cyclobutyl, -cyclopentyl, or -cyclohexyl, optionally substituted with a —NHSO 2 R x , wherein R., is as defined above,

(3) —NR o COR p , wherein R y is: (i) —C 1 to C 6 alkyl, -cyclopropyl, -cyclobutyl, -cyclopentyl, or -cyclohexyl, optionally substituted with: halogen, or -aryl, or (ii) -5 or 6 membered heterocycle, and wherein R o is a hydrogen,

(4) —NR q CONR q R r , wherein R q is: (1) -hydrogen, or (ii) —C 1 to C 6 alkyl, -cyclopropyl, -cyclobutyl, -cyclopentyl, or -cyclohexyl, and wherein R r is a C 1 to C 6 alkyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, optionally substituted with one or more of the following: (a) -halogen, (b) -alkenyl, or (c) -aryl, (iii) -cyclopropyl; (iv) -cyclobutyl; (v) -cyclopentyl; (vi) -cyclohexyl; or (vii) -cyclopropylmethyl;

(5) —NR t COOR u , wherein R u is: (i) —C 1 to C 12 alkyl, -cyclopropyl, -cyclobutyl, -cyclopentyl, or -cyclohexyl, optionally substituted with: (a) -aryl optionally substituted with a C 1 to C 6 alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or an alkoxy, (b) -alkenyl, (c) -alkoxy, (d) -alkynyl, (e) -halogen, or (f) -5 or 6 membered heterocycle, (ii) -aryl, optionally substituted with an alkoxy, (iii) -5 or 6 membered heterocycle, (iv) -cyclopropyl, (v) -cyclobutyl, (vi) -cyclopentyl, (vii) -cyclohexyl, -cyclopropylmethyl, or (ix) -cyclopropylethyl, and wherein R t is: (i) -hydrogen, or (ii) —C 1 to C 6 alkyl, -cyclopropyl, -cyclobutyl, -cyclopentyl, or -cyclohexyl,

(6) —NR v SO 2 R w , wherein R v is a hydrogen, and wherein R w is a C 1 to C 6 alkyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, optionally substituted with a halogen;

wherein R 1 is a C 1 to C 6 alkyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, or

(13) —NHR bb , wherein R bb is a —PO(OR x ) 2 .

78 . The compound of claim 76 , wherein:

Z is: (a) —COOR x , wherein R x is as defined above;

(b) -cyclopropylmethyl;

(c) -cyclobutylmethyl; or

(d) -cyclopentylmethyl.

79 . The compound of claim 76 , wherein:

Z is: (a) -cyclopropyl;

(b) -cyclobutyl;

(c) -cyclopentyl; or

(d) -cyclohexyl.

80 . A pharmaceutical composition comprising the compound of claim 76 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.

81 . The pharmaceutical composition of claim 80 , further comprising one or more additional anti-viral agent selected from the group consisting of pegylated interferon, un-pegylated interferon, ribavirin or prodrugs or derivatives thereof, a glucosidase inhibitor, a protease inhibitor, a polymerase inhibitor, p7 inhibitors, an entry inhibitor, a fusion inhibitor, an anti-fibrotic, a caspase inhibitor, an inosine monophosphate dehydrogenase inhibitor, synthetic thymosin alpha 1, therapeutic vaccines, immunomodulators, a helicase inhibitor, a glycosidase inhibitor, a Toll-like receptor agonist and combinations thereof.

82 . A method for treating a viral infection in a subject in need thereof comprising administering an effective amount of the compound of claim 76 or a pharmaceutically acceptable salt thereof to the subject, wherein said viral infection is a Hepatitis C viral infection.

83 . A compound or a pharmaceutically acceptable salt thereof selected from the group consisting of:

84 . A pharmaceutical composition comprising the compound of claim 83 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.

85 . The pharmaceutical composition of claim 84 , further comprising one or more additional anti-viral agent selected from the group consisting of pegylated interferon, un-pegylated interferon, ribavirin or prodrugs or derivatives thereof, a glucosidase inhibitor, a protease inhibitor, a polymerase inhibitor, p7 inhibitors, an entry inhibitor, a fusion inhibitor, an anti-fibrotic, a caspase inhibitor, an inosine monophosphate dehydrogenase inhibitor, synthetic thymosin alpha 1, therapeutic vaccines, immunomodulators, a helicase inhibitor, a glycosidase inhibitor, a Toll-like receptor agonist and combinations thereof.

86 . A method for treating a viral infection in a subject in need thereof comprising administering an effective amount of the compound of claim 83 or a pharmaceutically acceptable salt thereof to the subject, wherein said viral infection is a Hepatitis C viral infection.